“As clinical validation of the orexin agonist class continues to grow, we believe Centessa (CNTA) is well positioned with a novel potential best-in-class OX2R agonist pipeline aimed at redefining the standard of care. This includes not only restoring normal wakefulness to meet the real-world needs of individuals with sleep-wake disorders, but also potentially addressing comorbidities such as excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across a range of neurological, neurodegenerative and neuropsychiatric conditions where there is unmet need,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Promising Outlook for Centessa Pharmaceuticals: ORX750’s Potential Differentiation and Efficacy Drive Buy Rating
- Alkermes narcolepsy trial results ‘encouraging’ for Centessa, says Leerink
- Centessa initiated with a Buy at Truist
- Positive Market Outlook for Centessa Pharmaceuticals Driven by Promising Developments in Orexin Agonist Class
- Optimistic Buy Rating for Centessa Pharmaceuticals Driven by Orexin Agonist Market Potential and Positive Safety Profile